Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the installation of a Senhance ® Surgical System in the Department of Gynecology at the University Hospital Tübingen.
RESEARCH TRIANGLE PARK, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical (formerly known as TransEnterix), Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the installation of a Senhance® Surgical System in the Department of Gynecology at the University Hospital Tübingen. The Department of Gynecology at the University Hospital Tübingen previously initiated its Senhance Surgical program in December of 2021, as announced by the Company on January 10, 2022. The system will be initially utilized by the Department of Gynecology at the University Hospital Tübingen. Independent of the lease and utilization agreement, the Department of Gynecology at the University Hospital Tübingen has entered into a research agreement with the Company focused on collecting procedural and outcomes data for certain gynecologic procedures performed with the Senhance system.
“We are very excited to be partnering with the Department of Gynecology at the University Hospital Tübingen, which is a leading institution in Germany, and Europe more broadly,” said Anthony Fernando, Asensus Surgical President, and CEO. “Tübingen’s gynecological surgery department is one of the most well respected in Europe, and we are proud they have decided to utilize Senhance within their state-of-the-art facilities.”
Asensus Surgical’s technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments.
“Gynecological procedures require a high level of precision and safety while at the same time utilizing small instruments due to the delicacy and size of the anatomy,” said Professor Diethelm Wallwiener, Medical Director of the Department of Gynecology at University Hospital Tübingen. “Senhance is a great addition to our gynecology department as it provides unparalleled minimally invasive surgery with the potential to use 3mm instruments as well as innovative surgical intelligence with the addition of the ISU.”
About the Department of Gynecology at the University Hospital Tübingen
The Department of Gynecology at the University Hospital Tübingen is one of the 35 university hospitals in Germany that contribute to the successful combination of high-performance medicine, research, and teaching. They are a reliable partner in four of the six German Centres for Health Research initiated by the Federal Government. They welcome patients from all over the world who are treated in their clinics and wish to benefit from their high standards in research, patient care and nursing.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.
Follow Asensus
- Email Alerts: https://ir.asensus.com/email-alerts
- LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc
- Twitter: https://twitter.com/AsensusSurgical
- YouTube: https://www.youtube.com/c/transenterix
- Vimeo: https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to the Senhance Surgical System and the Department of Gynecology at the University Hospital Tübingen initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the Senhance Surgical System will be a great addition to the Department of Gynecology at the University Hospital Tübingen, providing unparalleled minimally invasive surgery with the potential to use 3mm instruments as well as innovative surgical intelligence with the addition of the ISU. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Lauren Stredler, 847-271-6891
CG Life
lstredler@cglife.com
